Bausch Health Companies Inc. (BHC)

Market Cap	2.14B +12.1%
Revenue (ttm)	10.53B +8.2%
Net Income	-1.21B
EPS	-3.25
Shares Out	373.48M
PE Ratio	n/a
Forward PE	1.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,125,071
Open	5.66
Previous Close	5.65
Day's Range	5.65 - 5.89
52-Week Range	4.41 - 8.69
Beta	0.42
Analysts	Hold
Price Target	8.00 (+39.62%)
Earnings Date	Apr 29, 2026

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,300
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Analyst Summary

According to 3 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $8.0, which is an increase of 39.62% from the latest price.

Price Target

$8.0

(39.62% upside)

Analyst Consensus: Hold